Cargando…

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils

Background Myeloid dysfunction is an emerging hallmark of microenvironment changes occurring in multiple myeloma (MM). Our previous work showed that FcγRI/CD64 overexpression in neutrophils of newly diagnosed MM patients is associated to inferior outcomes, reduced oxidative bursts and phagocytosis,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romano, Alessandra, Parrinello, Nunziatina Laura, Parisi, Marina, Del Fabro, Vittorio, Curtopelle, Angelo, Leotta, Salvatore, Conticello, Concetta, Di Raimondo, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533128/ https://www.ncbi.nlm.nih.gov/pubmed/34680570 http://dx.doi.org/10.3390/biomedicines9101455

Ejemplares similares

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
por: Parisi, Marina Silvia, et al.
Publicado: (2019)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study
por: Del Fabro, Vittorio, et al.
Publicado: (2023)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Multiple Myeloma in 2023 Ways: From Trials to Real Life
por: Fazio, Manlio, et al.
Publicado: (2023)

A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
por: Markovic, Uros, et al.
Publicado: (2019)

Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
por: Conticello, Concetta, et al.
Publicado: (2019)

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
por: Puglisi, Fabrizio, et al.
Publicado: (2019)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Salvage Therapy of Multiple Myeloma: The New Generation Drugs
por: Romano, Alessandra, et al.
Publicado: (2014)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus
por: Li, Yi, et al.
Publicado: (2009)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Publicado: (2023)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
por: Tibullo, Daniele, et al.
Publicado: (2015)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
por: Markovic, Uros, et al.
Publicado: (2021)

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
por: Siegel, David S., et al.
Publicado: (2019)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
por: Oriol, A., et al.
Publicado: (2022)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

A62 IDENTIFICATION OF SPECIFIC COLONIC DEEP MUSCLE LAYER MACROPHAGES SUBSETS BY THE CD64 (FCΓRI) MARKER
por: Nishihara, Y, et al.
Publicado: (2023)

CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
por: Giallongo, Cesarina, et al.
Publicado: (2022)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

P852: ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMA CELLS
por: Romano, Alessandra, et al.
Publicado: (2023)

Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
por: Markovic, Uros, et al.
Publicado: (2021)

The Importance of Human FcγRI in Mediating Protection to Malaria
por: McIntosh, Richard S, et al.
Publicado: (2007)

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
por: Dimopoulos, Meletios, et al.
Publicado: (2020)

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection
por: Romano, Alessandra, et al.
Publicado: (2022)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma
por: Giallongo, Cesarina, et al.
Publicado: (2019)

Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
por: Barbato, Alessandro, et al.
Publicado: (2023)

Universal Antibody Conjugation to Nanoparticles Using the Fcγ Receptor I (FcγRI): Quantitative Profiling Of Membrane Biomarkers
por: Kim, Chloe, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jltmm199h5vhne78c03jn1gvc5